创始人
王喆 博士
创始人、董事长
王喆博士师从诺贝尔化学奖得主 E.J. Corey教授，从事药物开发研究工作20余年，有领导从立项到药物上市的完整产业链经验，在抗感染、抗病毒及抗癌新药研发领域有极深的造诣与卓越成就。
Founder
Dr. Zhe WANG
Founder, chairman
Dr. Zhe WANG studied under Prof. E.J. Corey, a Nobel laureate in chemistry.
With more than 20 years engaged in drug research and development, Dr. Zhe WANG has full experience of leading drug development from project initiation to drug launch. He has profound attainments and outstanding achievements in the field of new drug of anti-infection, anti-virus and anti-cancer.
研发体系
长森药业聚焦自身免疫疾病、肿瘤免疫治疗、抗病毒等领域的创新药研发与产业化，管线产品临床评估指标均达到国际领先水平，有望成为相关领域的重大突破（FIC，first in class）。
长森药业专注具有自主知识产权及国际领先水平的创新药物的开发和医学转化，通过合作开发、Licensing Out等形式，积极参与国际竞争，解决尚未满足的临床需求。
R&D
Longwood Biopharma is focusing on the development and industrialization of innovative drugs in the fields of autoimmune diseases, tumor immunotherapy and anti-virus. With world-class performance in clinical evaluation, our pipelines are expected to become a major breakthrough in related fields (FIC, first in class).
Longwood Biopharma focuses on the development and medical translation of world-class innovative drugs with independent IPR, and actively participates in international competition through co-development and licensing-out to address unmet clinical needs.
新闻资讯
【长森快讯】新一代口服JAK1选择性抑制剂LW402类风湿性关节炎临床II期研究结果展现惊人疗效
LW402在一项关于类风湿性关节炎（RA）的临床II研究已完成全部患者给药及数据采集，并展现惊人疗效...
【长森快讯】长森药业自主研发新一代口服JAK1选择性抑制剂LW402获批开展白癜风临床研究
近日，长森药业自主研发的新一代口服JAK1选择性抑制剂LW402获批开展白癜风临床研究。
【长森快讯】长森药业自主研发乙肝一类新药LW231在AASLD2023-The Liver Meeting发布最新数据
近日，长森药业在美国波士顿举行的AASLD2023-The Liver Meeting上分享了自主研发的乙肝一类新药LW231的最新研究海报。
News
【LWBP NEWS】Next-generation of Oral JAK1 Selective Inhibitor LW402 Demonstrates Surprising Efficacy in Rheumatoid Arthritis Phase II Clinical Study Results
Recently, LW402, a next-generation oral JAK1 selective inhibitor independently developed by LWBP, has completed all patient dosing and data collection in a Phase II clinical study on rheumatoid arthritis (RA), and obtained positive results...
【LWBP NEWS】LW402, a next-generation oral JAK1-selective inhibitor independently developed by LWBP, was approved for clinical studies in vitiligo
Recently, LW402 was approved to conduct clinical studies in vitiligo. LW402 is a next-generation highly selective JAK1 inhibitor independently developed by LWBP.
【LWBP NEWS】LWBP Releases Updated Data on LW231, a Self-Developed Novel Hepatitis B Drug, at AASLD2023-The Liver Meeting
LWBP shared the latest research poster of LW231, a self-developed novel Hepatitis B drug, at AASLD2023-The Liver Meeting held in Boston, USA.
